Role and mechanism of Roux-en-Y gastric bypass in the treatment of diabetic urinary bladder hyperactivity by reducing TRPV1 and P2X3

Figure 6 Detection of the mRNA and protein levels of transient receptor potential vanilloid type 1 and purinergic receptor P2X3 in bladder tissues. A: The mRNA expression level of transient receptor potential vanilloid type 1 (TRPV1); B: The mRNA expression level of purinergic receptor P2X3; C: Western blot representation of TRPV1 and P2X3; D: Protein expression level of TRPV1; E: Protein expression level of P2X3 (n = 8). ^aP < 0.05, overactive bladder (OAB) group compared with the sham group; ^bP < 0.05, Roux-en-Y gastric bypass (RYGB) group compared with the OAB group.